BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Bio NC

  COVID-19 News: Test for Asymptomatic People, Bemcentinib in Hospitalized COVID-19 Patients and More

  Please check out the biopharma industry’s COVID-19 stories that are trending for May 18, 2021.

  May 18, 2021

   · 

  5 min read

   · 

  BioSpace Editorial Staff
• 

  Drug Development

  FDA Torpedoes CytoDyn’s Leronlimab for COVID-19 with Rare Public Scolding

  The U.S. FDA scolded CytoDyn for misrepresenting its clinical trial results for Leronlimab in COVID-19. Here’s what FDA has to say regarding CytoDyn Leronlimab.

  May 18, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  BMS Makes Potential $1.56 Billion Commitment to Agenus’ Antibody Program

  Under the terms of the agreement, Bristol Myers Squibb will take over complete responsibility for the development and commercialization of AGEN1777 and any related products globally.

  May 18, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Pharm Country

  Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome

  DS occurs in about 1 in 700 newborns and approximately 200,000 people in the U.S. have the condition.

  May 18, 2021

   · 

  4 min read
• 

  Business

  Tamasek-Backed G2 Bio Companies Will Accelerate Gene Transfer Technologies

  Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.

  May 18, 2021

   · 

  2 min read

   · 

  Brandon May
• 

  Pharm Country

  Celmatix is Redefining the Ovary to Power Women’s Health

  Celmatix’s drug program works by mimicking anti-Mullerian hormone, which acts as the molecular break that keeps women from depleting their ovarian reserves too quickly.

  May 18, 2021

   · 

  5 min read

   · 

  Heather McKenzie
• 

  FDA

  Enbrel Battle Ends as Supreme Court Refuses to Hear Sandoz Appeal

  The high court’s decision will prevent Sandoz from launching its biosimilar to Amgen’s blockbuster rheumatoid arthritis drug.

  May 18, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Medicago’s Plant-Based Vaccine Combined with GSK’s Adjuvant Tech Shines in Phase II

  Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.

  May 18, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Funding News: Three Biopharmas Score a Combined $261 Million to Advance Pipelines

  Three companies on different continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.

  May 18, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  New Study Identifies Brain Proteins Predictive of Future Dementia

  A new study from Johns Hopkins University Bloomberg School of Public Health suggests the development of dementia is associated with abnormal levels of plasma proteins, and these proteins may be predictive of dementia up to five years before a patient receives a diagnosis.

  May 18, 2021

   · 

  3 min read

   · 

  Brandon May